会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • BIOMARKERS FOR AGGRESSIVE PROSTATE CANCER
    • 生物标志物用于肿瘤前列腺癌
    • WO2012129408A2
    • 2012-09-27
    • PCT/US2012/030129
    • 2012-03-22
    • THE JOHNS HOPKINS UNIVERSITYZHANG, HuiTIAN, YuanCHAN, Daniel W.CHEN, Jing
    • ZHANG, HuiTIAN, YuanCHAN, Daniel W.CHEN, Jing
    • G01N33/53G01N33/68G01N33/574
    • G01N33/6893G01N33/57434
    • The present invention relates to the field of biomarkers and, more specifically, to biomarkers useful in diagnosing aggressive prostate cancer. In specific embodiments, a method for diagnosing aggressive prostate cancer in a patient comprises (a) measuring the levels of one or more biomarkers in a sample collected from the patient; and (b) comparing the levels of the one or more biomarkers with predefined levels of the same biomarkers that correlate to a patient having aggressive prostate cancer and predefined levels of the same biomarkers that correlate to a patient not having aggressive prostate cancer, wherein a correlation to one of the predefined levels provides the diagnosis. In a specific embodiment, the one or more biomarkers may comprise cathepsin-L (CTSL), periostin, microfibrillar-associated protein 4 (MFAP4), collagen XII, neprilysin, clusterin, neutrophil gelatinase associated lipocalin (NGAL), epithelial cell activating molecule (EpCAM), prostate specific antigen (PSA), membrane metallo-endopeptidase (MME) and asporin (ASPN).
    • 本发明涉及生物标记领域,更具体地涉及可用于诊断侵略性前列腺癌的生物标志物。 在具体实施方案中,用于诊断患者中侵袭性前列腺癌的方法包括(a)测量从患者收集的样品中的一种或多种生物标志物的水平; 和(b)将一种或多种生物标志物的水平与与具有侵袭性前列腺癌的患者相关的相同生物标志物的预定水平和与不具有侵袭性前列腺癌的患者相关的相同生物标志物的预定水平进行比较,其中相关性 到其中一个预定义的级别提供诊断。 在一个具体的实施方案中,一种或多种生物标志物可以包含组织蛋白酶-L(CTSL),骨膜素,微原纤维相关蛋白4(MFAP4),胶原XII,起泡蛋白,聚集蛋白,嗜中性粒细胞明胶酶相关脂质运载蛋白(NGAL),上皮细胞活化分子 EpCAM),前列腺特异性抗原(PSA),膜金属内肽酶(MME)和阿泊菌(ASPN)。